Data-driven drug development company Emyria has appointed former Jazz Pharmaceuticals chief medical officer (CMO) and head of R&D Dr Karen Smith as chair of its strategic advisory board.
Smith has held key CEO and CMO roles at biotech and pharmaceutical development companies globally.
Emyria managing director Dr Michael Winlo said: “Dr. Smith is a highly acclaimed and respected pharmaceutical executive, who has overseen multiple successful drug registrations.
“We believe Dr. Smiths’ background in successful product registration and strategic partnerships in biopharma will benefit Emyria’s globally-focussed drug registration initiatives, including our EMD-003 product candidate for psychological distress and the symptoms of anxiety, depression and stress.”
Smith added: “I’m passionate about supporting innovative ways to accelerate drug development. Emyria has built a unique clinical service and evidence-generating model that has the potential to accelerate drug development for patients with unmet needs.”
Jazz Pharmaceuticals recently acquired GW Pharma for US$7.2B.